September 2 2011 | Category: Appointment
Bunnik, The Netherlands, 2 September 2011. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for the treatment of severe inflammatory diseases, today announced the appointment of Erik van den Berg, previously VP Business Development of AM-Pharma as CEO of the company.
Bart Wuurman, who has led the company the past 4 years decided to take on a new challenge in his career.
Eric Claassen, Chairman of AM-Pharma, commented:
“Bart has made a distinctive contribution to the development of AM-Pharma and I would like to thank him for his efforts in turning AM-Pharma into a focused organization, and for his role in preparing a new round of upcoming financing for the company.”
Bart Wuurman, said:
“I am proud to have worked with the AM Pharma team during the past four years. In this period the team was able to generate key clinical data that supports further development of AM-Pharma’s product for an indication of high medical need.”